SOLIGENIX, INC. (SNGX) Form 424B3 — Aug 7, 2026
Soligenix filed Prospectus Supplement No. 2 to register the resale of up to 1,054,688 shares issuable upon exercise of previously issued common warrants, and the supplement incorporates its Form 10-Q for the quarter ended June 30, 2026. The company terminated its lead HyBryte (synthetic hypericin) program for cutaneous T-cell lymphoma in June 2026 after the Data Monitoring Committee recommended halting the Phase 3 FLASH2 trial for futility at an interim analysis in April 2026, with approximately $70,000 in wind-down charges expected.
Key figures
- Revenue
- 0
- Total Assets
- 10499470
- Cash Position
- 9811141
- Shares Outstanding
- 21765479
- Cash runway
- into the second quarter of 2028
- Working capital
- 6499947
- Accumulated deficit
- 249863451
- Atm july 2026 shares
- 128000
- Atm shares sold h1 2026
- 11538661
- Nasdaq compliance deadline
- December 7, 2026
- Atm weighted avg price h1 2026
- 0.54
- Anti dilutive options june 30 2026
- 890119
- Hybryte wind down charges estimate
- 70000
- Anti dilutive warrants june 30 2026
- 6798141
- Atm remaining capacity july 31 2026
- approximately $2.4 million
- Warrant shares registered for resale
- 1054688
- Atm july 2026 weighted avg fair value
- 0.4
- Atm gross proceeds sold through june 30 2026
- 6234000
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.